Cargando…

Safety enhancement in adult body computed tomography scanning: comparison of iodixanol versus iohexol

BACKGROUND: The aim of this study was to compare the safety and intra-individual contrast enhancement of low-osmolar monomeric iohexol and the iso-osmolar dimeric iodixanol in body computed tomography (CT) scanning. METHODS: In this single center, double-blind, prospective study, a total of 2000 con...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yong, Zeng, Guofei, Liu, Xi, Peng, Cong, Lai, Changsu, Zhou, Peihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766145/
https://www.ncbi.nlm.nih.gov/pubmed/27026845
http://dx.doi.org/10.1186/s40064-016-1754-z
Descripción
Sumario:BACKGROUND: The aim of this study was to compare the safety and intra-individual contrast enhancement of low-osmolar monomeric iohexol and the iso-osmolar dimeric iodixanol in body computed tomography (CT) scanning. METHODS: In this single center, double-blind, prospective study, a total of 2000 consecutive patients undergoing adult body CT scanning were prospectively enrolled, with 1000 patients assigned to iodixanol and 1000 patients assigned to iohexol. In both groups, the contrast medium was injected at the rate of 3.5 ml/s. Subjective assessment of image quality for each image was determined using a 3-grading scale by three reviewers. Patients were monitored with questioning and vital signs before injection, immediately after injection, and at 24 and 48 h. Extensive laboratory evaluation also was performed. RESULTS: Laboratory results showed no significant difference across groups. There were also no detectable differences in image quality between the two contrast groups in this study. The total adverse reactions occurred in less than 1 % of individuals receiving iodixanol comparing to 2.5 % in iohexol group (P < 0.05). Among them, only 0.7 % patients injecting iodixanol suffered immediate events, comparing to 2 % patients in iohexol group. In all, 0.2 % patients with iodixanol and 0.5 % with iohexol had late allergic reaction. Further, No deaths occurred in any of the two groups. CONCLUSIONS: The iso-osmolar iodixanol provides image quality compared with that of iohexol, with lower incidence of adverse events.